American Society of Hematology (ASH)

The American Society of Hematology (ASH) is a professional organization representing hematologists. It was founded in 1958. Its annual meeting is held in December of every year and has attracted more than 30,000 attendees. The society publishes the medical journal Blood, the most cited peer-reviewed publication in the field, which is available weekly in print and online, as well as the newly launched, online, peer-reviewed open-access journal, Blood Advances.

Combined Venetoclax and Ibrutinib for Patients with Previously Untreated, High-Risk CLL and Relapsed/Refractory CLL: A Phase 2 Trial

ASH 2017 – CLL

The combination of ibrutinib and venetoclax is safe and effective in patients with chronic lymphocytic leukemia (CLL), with a 100% overall response rate and acceptable toxicities. Read More ›

A Multicenter, Phase 2 Study of Ibrutinib plus FCR as Frontline Therapy for Younger Patients with CLL

ASH 2017 – CLL

A multicenter phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab (FCR) as frontline therapy for younger patients with relatively high-risk chronic lymphocytic leukemia (CLL) showed that this combination resulted in superior rates of complete remission and bone marrow minimal residual disease negativity compared with FCR alone, with acceptable levels of toxicity. Read More ›

Initial Results of the Phase 2 Treatment-Naïve Cohort in a Phase 1b/2 Study of Obinutuzumab, Ibrutinib, and Venetoclax in CLL

ASH 2017 – CLL

The combination of obinutuzumab, ibrutinib, and venetoclax for 25 treatment-naïve patients with chronic lymphocytic leukemia (CLL) was safe and resulted in a 96% overall response rate, with a 52% rate of complete remission and a 58% rate of minimal residual disease negativity in blood and bone marrow after 8 cycles of therapy. Read More ›

Acalabrutinib Monotherapy in Patients with Relapsed/Refractory CLL: Updated Results from the Phase 1/2 ACE-CL-001 Study

ASH 2017 – CLL

In an update of the phase 1/2 ACE-CL-001 study, patients with relapsed/refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma treated with acalabrutinib monotherapy demonstrated high response rates (overall response, 85%; 18-month duration of response, 85%; 18-month progression-free survival, 88%), with an acceptable safety profile. Read More ›

Identification of Baseline Characteristics That Predict Good Outcome of alloHCT in Young CLL Patients - A Retrospective Analysis from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation

ASH 2016 – CLL

The most important positive prognostic factor for 2-year nonrelapse mortality in chronic lymphocytic leukemia (CLL) patients following allogeneic hematopoietic stem-cell transplantation (alloSCT) is the donor HLA match. AlloSCT still remains a valid option for younger, high cytogenetic risk, refractory/relapsed CLL patients with an HLA-allele well-matched donor. Read More ›

5-Year Ibrutinib Therapy in Treatment-Naïve Patients with Relapsed or Refractory CLL or SLL

ASH 2016 – CLL

After 5 years of follow-up, single-agent ibrutinib continues to show durable responses in patients with treatment-naive or relapsed/refractory chronic lymphocytic leukemia/small lymphocytic leukemia, including those with del17p, del11q, or unmutated IGVH. Read More ›

Updated Safety and Efficacy Data for Ibrutinib as First-Line Treatment in Older Patients with CLL or SLL

ASH 2016 – CLL

With a median time on study of 28.6 months, ibrutinib demonstrated an 88% reduction in risk of progression or death in an elderly chronic lymphocytic leukemia/small lymphocytic leukemia patient population, with treatment-limiting adverse events decreasing in frequency with longer follow-up. Read More ›

Nivolumab Combined with Ibrutinib for CLL and Richter Transformation: A Phase II Trial

ASH 2016 – CLL

The combination of nivolumab and ibrutinib has activity in patients with relapsed, refractory chronic lymphocytic leukemia (CLL) and Richter transformation. Read More ›

Outcomes of Ibrutinib Therapy by Age in Patients with CLL/SLL: Analyses from Phase 3 Trial Data (RESONATE and RESONATE-2)

ASH 2016 – CLL

Progression-free survival for treatment-naive ibrutinib-treated chronic lymphocytic leukemia/small lymphocytic leukemia (CLL/SLL) patients was similar regardless of age subgroup, whereas it was shorter for chlorambucil-treated patients aged ≥75 years compared with those aged 65 to Read More ›

11q Deletion (del11q) Is Not a Prognostic Factor for Adverse Outcomes for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with Ibrutinib: Pooled Data from 3 Randomized Phase 3 Studies

ASH 2016 – CLL

In pooled data from 3 randomized studies, the benefit of ibrutinib on progression-free and overall survival is most marked in patients with CLL/SLL with del11q, which is not the case with ofatumumab, chlorambucil, or bendamustine/rituximab. Read More ›

American Society of Hematology (ASH)

Page 27 of 44